BAF312AUS02: Exploring the Safety and Tolerability of Conversion from Oral or Injectable Disease Modifying Therapies to Dose Titrated Oral Siponimod in Patients with Advancing Forms of Relapsing Multiple Sclerosis: A 6-Month Open Label, Multicenter Phase IIIb Study (EXCHANGE)

Summary

To assess early phase safety and tolerability of converting patients from approved oral and injectable RMS DMTs to siponimod. The results of this study will guide clinically relevant decisions related to the transition from frequently used RMS DMTs to siponimod and provide clinically relevant data on safety and tolerability for healthcare providers who are considering converting patients from currently approved RMS DMT to siponimod.

More information

Contact us

To learn more about clinical trials at ProHealth Care, email research.institute@phci.org or call 262-928-3447.

Quick Access Links